GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Shiller PE Ratio

Cytokinetics (FRA:KK3A) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cytokinetics Shiller PE Ratio Historical Data

The historical data trend for Cytokinetics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Shiller PE Ratio Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cytokinetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cytokinetics's Shiller PE Ratio

For the Biotechnology subindustry, Cytokinetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Shiller PE Ratio falls into.



Cytokinetics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cytokinetics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cytokinetics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.224/131.7762*131.7762
=-1.224

Current CPI (Mar. 2024) = 131.7762.

Cytokinetics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.169 100.560 -0.221
201409 -0.124 100.428 -0.163
201412 0.187 99.070 0.249
201503 -0.213 99.621 -0.282
201506 -0.241 100.684 -0.315
201509 -0.205 100.392 -0.269
201512 -0.220 99.792 -0.291
201603 -0.278 100.470 -0.365
201606 -0.258 101.688 -0.334
201609 0.686 101.861 0.887
201612 0.152 101.863 0.197
201703 -0.580 102.862 -0.743
201706 -0.534 103.349 -0.681
201709 -0.503 104.136 -0.637
201712 -0.634 104.011 -0.803
201803 -0.454 105.290 -0.568
201806 -0.437 106.317 -0.542
201809 -0.343 106.507 -0.424
201812 -0.422 105.998 -0.525
201903 -0.478 107.251 -0.587
201906 -0.496 108.070 -0.605
201909 -0.454 108.329 -0.552
201912 -0.459 108.420 -0.558
202003 -0.597 108.902 -0.722
202006 -0.604 108.767 -0.732
202009 -0.042 109.815 -0.050
202012 -0.510 109.897 -0.612
202103 -0.554 111.754 -0.653
202106 -0.714 114.631 -0.821
202109 -0.808 115.734 -0.920
202112 -0.319 117.630 -0.357
202203 -0.953 121.301 -1.035
202206 -0.218 125.017 -0.230
202209 -1.535 125.227 -1.615
202212 -1.369 125.222 -1.441
202303 -1.289 127.348 -1.334
202306 -1.237 128.729 -1.266
202309 -1.265 129.860 -1.284
202312 -1.265 129.419 -1.288
202403 -1.224 131.776 -1.224

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cytokinetics  (FRA:KK3A) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cytokinetics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (FRA:KK3A) Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines